NEW YORK and MELBOURNE, Australia, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today
announced completion of the transaction with Tasly Pharmaceutical Group to establish a strategic partnership in China for
Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product candidates MPC-150-IM for heart failure and MPC-25-IC for heart
attacks.
Mesoblast has received US$40 million (AUD$57 million) from Tasly, comprising an upfront technology access fee of US$20 million
and an equity purchase of US$20 million for which Mesoblast Limited has issued 14,464,259 fully paid ordinary shares to Tasly.
As consideration, Tasly has received exclusive rights and will fund all development, manufacturing and commercialization activities
in China for MPC-150-IM for the treatment and prevention of chronic heart failure and MPC-25-IC for the prevention and treatment of
acute myocardial infarction. Mesoblast will receive US$25 million on achievement of product regulatory approvals in China,
double-digit escalating royalties on net product sales, and six additional escalating milestone payments upon the product
candidates reaching certain sales thresholds.
Mesoblast and Tasly will establish a joint steering committee, with equal representation from both parties, to oversee, review and
coordinate the development, manufacturing and commercialization activities for the cardiovascular product candidates in China. The
parties, through the joint steering committee, plan to expedite development and commercialization of these cardiovascular product
candidates by leveraging each other’s clinical trial results in China, and the United States and other major jurisdictions
respectively to support their respective regulatory submissions for MPC-150-IM and MPC-25-IC.
Chairman of Tasly Pharmaceutical Group Mr Yan Kaijing said: "We believe Mesoblast’s cellular medicine technology platform is poised
to transform cardiovascular care in China. This is why Tasly has made this strategic investment and long-term partnership with the
premier global cellular medicine company.”
Mesoblast Chief Executive Dr Silviu Itescu stated: “We are very excited to be partnering with Tasly, one of the largest
pharmaceutical companies in China, the world’s fastest growing biopharmaceutical and healthcare market.”
About Tasly Pharmaceutical Group
Tasly Pharmaceutical Group (SHA: 600535) is one of the largest pharmaceutical companies in China with more than 20
years of operational history. Its business focuses on R&D, manufacturing and commercialization of innovative modern traditional
Chinese medicine, biologics and chemical drugs in the therapeutic areas of cardiology, metabolism and oncology. Tasly has the only
marketed biological product for cardiovascular diseases approved in China. It has one of the largest pharmaceutical sales and
marketing teams, including 809 offices established in 29 regions covering all the main therapeutic areas, and a vast distribution
network across approximately 20,000 hospitals in China. At 2017, its total annual revenues exceeded US$2.5 billion.
About Mesoblast
Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company
has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three
product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to
degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from
the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses
from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need
for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian
Securities Exchange (MSB) and on the Nasdaq (MESO). www.mesoblast.com
Forward-Looking Statements
This announcement includes forward-looking statements that relate to future events or our future financial performance and involve
known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or
achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by
these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995 and other applicable federal securities laws. Forward- looking statements include, but are
not limited to, statements about: the potential benefits of this alliance and the parties’ ability to maintain the alliance; the
parties’ ability to advance product candidates into, enroll and successfully complete, clinical studies, advance their
manufacturing capabilities, and obtain regulatory filings and approvals. There are many uncertainties and risks that may cause our
actual results, performance or achievements to be materially different from those which may be expressed or implied by such
statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any
obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future
developments or otherwise.
For further information, please contact:
